EP1709008A1 - Sels des inhibiteurs de hmg-coa reductase et leur utilisation - Google Patents

Sels des inhibiteurs de hmg-coa reductase et leur utilisation

Info

Publication number
EP1709008A1
EP1709008A1 EP05702276A EP05702276A EP1709008A1 EP 1709008 A1 EP1709008 A1 EP 1709008A1 EP 05702276 A EP05702276 A EP 05702276A EP 05702276 A EP05702276 A EP 05702276A EP 1709008 A1 EP1709008 A1 EP 1709008A1
Authority
EP
European Patent Office
Prior art keywords
rosuvastatin
formula
amine
optionally substituted
methylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05702276A
Other languages
German (de)
English (en)
Inventor
Yatendra Kumar
Mohammad Rafeeq
Shantanu De
Swargam Sathyanarayana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1709008A1 publication Critical patent/EP1709008A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Definitions

  • the present invention relates to salts of HMG CoA reductase inhibitors ⁇ and in particular, rosuvastatin amine salts and their use as intermediates in the preparation of rosuvastatin calcium.
  • Rosuvastatin is (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(l-methylethyl)-2-[methyl (methylsulfonyl)amino]-5- ⁇ yrimidinyl]-3,5-dihydroxy-6-heptenoic acid, shown as Formula II below, wherein R is a hydrogen atom.
  • Rosuvastatin or its pharmaceutically acceptable salts such as rosuvastatin calcium of Formula Ila (wherein R is calcium) and rosuvastatin magnesium of Formula lib (wherein R is magnesium) are antihypercholesterolemic drugs used in the treatment of atherosclerosis.
  • U.S. Patent No. RE 37,314 describes a process for the preparation of amorphous rosuvastatin calcium by dissolving the corresponding sodium salt in water, adding calcium chloride and collecting the resultant precipitate by filtration.
  • U.S. Patent No. 6,589,959 describes a process for the preparation of crystalline Form A of rosuvastatm by warming amorphous rosuvastatin calcium in a mixture of water and acetonitrile, cooling the resultant solution to ambient temperature, and then filtering the product which is then dried at 50°C under vacuum to give crystalline Form A of rosuvastatin calcium.
  • PCT patent application WO 01/60804 describes the preparation of crystalline rosuvastatin salts, namely, ammonium, methylammonium, ethylammonium, diethanolammonium, tri(hydroxymethyl)-methylammonium, benzylammonium, 4-methoxybenzylammonium, lithium and magnesium salts of crystalline rosuvastatin.
  • a process for preparation of rosuvastatin calcium from all these salts is also described in this patent application.
  • rosuvastatin which can be useful as intermediates in the preparation of pharmacologically acceptable salts of rosuvastatin, such as rosuvastatin calcium or rosuvastatin magnesium.
  • processes for the preparation of amine salts of rosuvastatin Also provided herein are processes of converting amine salts of rosuvastatin to pha ⁇ naceutically acceptable salts of rosuvastatin, such as calcium or magnesium.
  • pharmaceutical compositions comprising amine salts of rosuvastatin along with pharmaceutically acceptable excipients and/or carriers and methods of treatment of disease in which HMG-CoA reductase is implicated.
  • amine salts of rosuvastatin of Formula I refers to an amine salt or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NRiR R wherein independently R 1; R 2 and R 3 are H, straight or branched chain C S alkyl or hydroxyalkyl, C 3 . 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R ? R 2 and R 3 can combine with each other to form a C 3 .
  • rosuvastatin of Formula II refers to the free acid of rosuvastatin, wherein R" is of Formula A and R is hydrogen or lactone form of compound of Formula II wherein R" is of Formula B.
  • R in Formula A is selected from metal ions capable of forming a salt or an amino acid residue and esters of rosuvastatin wherein R in Formula A is selected from optionally substituted - 5 alkyl, aryl, cycloalkyl and heterocyclic residues.
  • R in Formula A is selected from optionally substituted - 5 alkyl, aryl, cycloalkyl and heterocyclic residues.
  • the term also covers compounds of Formula II which can be present in crystalline, solvate, hydrate or amorphous form thereof.
  • Figure 1 is an X-ray diffraction pattern of the cyclohexyl ammonium salt of rosuvastatin, as prepared in Example 1.
  • Figure 2 is an X-ray diffraction pattern of the diisopropyl ammonium salt of rosuvastatin, as prepared in Example 2.
  • Figure 3 is an X-ray diffraction pattern of the isopropyl ammonium salt of rosuvastatin, as prepared in Example 3.
  • Figure 4 is an X-ray diffraction pattern of the dicyclohexyl ammonium salt of rosuvastatin, as prepared in Example 4.
  • Figure 5 is an X-ray diffraction pattern of the (S) (+)- D-methylbenzyl ammonium salt of rosuvastatm, as prepared in Example 5.
  • Figure 6 is an X-ray diffraction pattern of amorphous rosuvastatin calcium, as prepared in Example 6, step b).
  • Figure 7 is an X-ray diffraction pattern of crystalline rosuvastatin calcium, as prepared in Example 6, step c).
  • Figure 8 is an X-ray diffraction pattern of crystalline rosuvastatin magnesium, as prepared in Example 7.
  • amine salts of rosuvastatin of Formula I or solvate, hydrate, crystalline or amorphous forms thereof are provided, in which the amine residue has the formula NRiR R 3 wherein independently R 1 ⁇ R 2 and R 3 are H, straight or branched chain CM S alkyl or hydroxyalkyl, C 3 . 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyL alkylcycloalkyl, or independently R l5 R 2 and R 3 can combine with each other to form a C 3 .
  • amine salts of rosuvastatin of Formula I having purity above 99% and diastereomeric impurity less than 0.5%, are also provided, for example, with purity more than 99.5% and diastereomeric impurity less than 0.25%, or with purity more than 99.75% and diastereomeric impurity less than 0.15%.
  • a process for preparation of amine salts of rosuvastatin of Formula I comprises: a) treating rosuvastatin of Formula II with an amine of Formula NR 1 R 2 R 3 wherein independently R l5 R 2 and R 3 are H, straight or branched chain C S alkyl or hydroxyalkyl, C 3 . 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl or independently R l5 R 2 and R 3 can combine with each other to form a C 3 .
  • Rosuvastatin of Formula II can be dissolved or suspended in an organic solvent and to this mass can be added an amine of Formula NR ⁇ R 2 R 3 wherein R l5 R 2 and R 3 are as defined above at a temperature of from about -50 to about 100°C.
  • Amine salts of rosuvastatin of Formula I can precipitate from the reaction mass after stirring, which is then isolated, for example, by filtration.
  • the product can optionally be washed with a second organic solvent, in which compounds of Formula I are insoluble or very slightly soluble or sparingly soluble.
  • the product can then suitably be dried to get amine salts of rosuvastatin of Formula I in pure form, which can be further purified by crystallization or any other suitable method such as column chromatography.
  • the organic solvent used in the reaction is characterized by the fact that rosuvastatin of Formula II is very soluble or soluble in it whereas amine salts of rosuvastatin of Formula I are slightly soluble, very slightly soluble or insoluble in such solvent.
  • organic solvents are: esters such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate and isobutyl acetate; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone; and chlorinated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and ethylene dichloride.
  • esters such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate and isobutyl acetate
  • ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone
  • chlorinated hydrocarbons such as methylene chloride, chloroform
  • the second organic solvent in which amine salts of rosuvastatin of Formula I are insoluble (10,000 and over parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) or very slightly soluble (form 1,000 to 10,000 parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) or sparingly soluble (from 30 to 100 parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) can be, for example, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof.
  • amine salts of rosuvastatin of Formula I or solvate, hydrate, crystalline or amorphous form thereof are provided, in which the amine residue has a Formula NRtRaRa (wherein independently R l5 R and R 3 are H, straight or branched chain C ⁇ -15 alkyl or hydroxyalkyl, C 3 - 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R ls R 2 and R 3 can combine with each other to form a C 3 .
  • Formula NRtRaRa wherein independently R l5 R and R 3 are H, straight or branched chain C ⁇ -15 alkyl or hydroxyalkyl, C 3 - 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R
  • Formula I are straightforward and simpler, as compared to processes described in, for example, PCT application WO 01/60804, with respect to the number and quantity of solvents used, reaction time and temperature, purity of product obtained and ease of isolating the final product.
  • the amine salts of Formula I as prepared by processes provided herein can be isolated as crystalline solids having a purity of at least above
  • processes for the preparation of amorphous or crystalline rosuvastatin calcium of Formula Ila from amine salt of Formula I are provided herein, wherein the process comprises: a) treating an amine salt of a compound of Formula I with an acid; b) optionally isolating rosuvastatm acid or a lactone thereof; c) adding a base and calcium ions; d) isolating amorphous rosuvastatin calcium; and e) optionally converting amorphous rosuvastatin calcium to crystalline rosuvastatin calcium.
  • Rosuvastatin amine salt of Formula I can be treated with an acid, at a pH of about 1 to about 4, to get rosuvastatin lactone, or at pH of about 4.5 to about 5, to get rosuvastatin acid.
  • the reaction can be carried out in the presence of a first organic solvent, optionally containing water, at a temperature of from about -10 to about 100°C. After completion of the reaction, the layers are separated and organic layer after washing with water and/or brine is concentrated completely under vacuum.
  • the residue obtained when the reaction pH is adjusted between 4.5 to 5 gives rosuvastatin acid as an oily liquid, which can then be dissolved in water and a first organic solvent, and treated with a base and calcium ions to give rosuvastatin calcium, which precipitates from the reaction mass as amorphous solid.
  • the mixture can be stirred at a temperature of about 40 to about 150°C for about 1 to about 50 hours to effect lactonization.
  • the second organic solvent can be removed from the reaction mass, for example, under vacuum, and the residue can be treated with second organic solvent to get the rosuvastatin lactone.
  • the residue can be as such taken in the next step without actually isolating the lactone.
  • the acid can be, for example, an inorganic mineral acid such as hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid; or an organic acid such as formic acid, acetic acid and the like.
  • the first organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents, alkyl, aromatic or cycloalkyl hydrocarbons or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol, isobutanol, n-butanol and n-propanol.
  • the ethers can be, for example, tetrahydrofuran, 1,4-dioxane, diethyl ether and diisopropyl ether.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N-methylpyrrolidone.
  • Alkyl, aromatic or cycloalkyl hydrocarbons can be, for example, toluene, benzene, xylene, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane or mixtures thereof.
  • the second organic solvent (characterized by the fact that rosuvastatin is insoluble or very slightly soluble or sparingly soluble in it) can be, for example, isopropanol, isobutanol, n-butanol, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof.
  • the lactone can then be dissolved in an organic solvent, optionally containing water, and treated with a base at a temperature of about 10 to about 70°C for about 1 to about 40 hours to effect hydrolysis of the lactone.
  • the reaction mass pH during the reaction can be adjusted to within the range of about 7.5 to about 11 using a base.
  • the solvent can then be removed and the residue can be taken up in water.
  • the aqueous solution can be washed with the first organic solvent as described earlier, and then treated with calcium ions, after which rosuvastatm calcium can precipitate from the aqueous solution as the amorphous solid.
  • the base can be, for example, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate or potassium bicarbonate.
  • the calcium ions can be generated by using a calcium compound which can be, for example, calcium chloride, calcium hydroxide, calcium carbonate, calcium acetate, calcium sulphate, calcium borate, calcium tartarate, calcium bromide or any other compound capable of generating calcium ions.
  • a process for the preparation of amorphous rosuvastatin calcium from amine salt rosuvastatm of Formula I is provided. The process comprises: a) treating an amine salt of rosuvastatin with a base and a calcium ions; and b) isolating amorphous rosuvastatin calcium from the reaction mass. Examples of base and calcium ion generating compounds are described in detail above.
  • the conversion can be easily carried out in presence of water, optionally containing an organic solvent.
  • the reaction temperature can be kept at about -5 to about 100°C.
  • the organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents, alkyl or cycloalkyl hydrocarbons or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol, isobutanol, n-butanol and n- propanol.
  • the ethers can be, for example, tetrahydrofuran, 1,4-dioxane, diethyl ether and diisopropyl ether.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N- methylpyrrolidone.
  • Alkyl or cycloalkyl hydrocarbons can be, for example, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane or mixtures thereof.
  • the amorphous rosuvastatin calcium prepared as described above can have a purity of at least 99%, having less than 0.5% of diastereomeric impurity. It can then be crystallized by, for example, methods described in the US Patent No. 6,589,959, to get crystalline rosuvastatin calcium which can be further converted to amorphous rosuvastatin calcium by, for example, methods described in Indian application 1304/DEL/2003.
  • processes for the preparation of amorphous or crystalline rosuvastatin magnesium of Formula lib from amine salt of Formula I comprise: a) treating an amine salt of a compound of Formula I with an acid; b) optionally isolating rosuvastatin acid or a lactone thereof; c) adding a base and magnesium ions; d) isolating crystalline rosuvastatin magnesium; and e) optionally converting crystalline rosuvastatin magnesium to amorphous rosuvastatin magnesium.
  • the process is similar to that described earlier, however magnesium ions are used to prepare rosuvastatin magnesium instead of calcium ions.
  • the product obtained is crystalline rosuvastatin magnesium unlike the amorphous form obtained in case of rosuvastatin calcium.
  • the magnesium ions can be generated by using a magnesium compound such as, for example, magnesium chloride, magnesium hydroxide, magnesium carbonate, magnesium acetate, magnesium sulphate, magnesium borate, magnesium tartarate, magnesium bromide or any other compound capable of generating magnesium ions.
  • processes for the preparation of amorphous rosuvastatin magnesium from amine salt of rosuvastatin of Formula I are provided. The processes comprise: a) treating an amine salt of rosuvastatin with a base and a magnesium ions; and b) isolating the crystalline rosuvastatm magnesium from the reaction mass.
  • the process is similar to that described earlier, however, magnesium ions are used to prepare rosuvastatin magnesium instead of calcium ions.
  • the product obtained is crystalline rosuvastatin magnesium unlike the amorphous form obtained in case of rosuvastatin calcium.
  • the crystalline forms of rosuvastatin magnesium obtained above can be converted to amorphous rosuvastatin magnesium by, for example, processes described in hidian application 1304/DEL/2003.
  • highly pure rosuvastatin calcium or rosuvastatin magnesium in crystalline or amorphous form thereof is provided, having a purity of at least 99.5% and diastereomeric impurity less than 0.25%.
  • a cyclohexyl ammonium salt of Formula I (wherein R ⁇ and R 2 are hydrogen and R is cyclohexyl group) is provided.
  • the cyclohexyl ammonium salt of Fo ⁇ nula I has the X-ray diffraction pattern (XRD) as provided in Figure 1.
  • a diisopropyl ammonium salt of Formula I (wherein R ⁇ and R 2 are isopropyl groups and R 3 is hydrogen) is provided.
  • the diisopropyl ammonium salt of Fo ⁇ nula I has the X-ray diffraction pattern (XRD) as provided in Figure 2.
  • an isopropyl ammonium salt of Formula I (wherein R ⁇ and R 2 are hydrogen and R 3 is isopropyl) is provided.
  • the isopropyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 3.
  • a dicyclohexyl ammonium salt of Formula I (wherein Ri and R are cyclohexyl groups and R 3 is hydrogen) is provided.
  • the dicyclohexyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 4.
  • an (S) (+)- G-methylbenzyl ammonium salt of Formula I (wherein R ⁇ and R 2 are hydrogen and R 3 is (S) (+)- D-methylbenzyl group) is provided.
  • the (S) (+)- D-methylbenzyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 5.
  • pharmaceutical compositions comprising amine salts of rosuvastatin of Formula I with a pharmaceutically acceptable diluent or carrier are provided.
  • a method of treating disease conditions wherein HMG-CoA is implicated comprises of administering to a mammal in need thereof a therapeutically effective amount of amine salt of rosuvastatin of Formula I.
  • Example 1 Preparation of Rosuvastatin Cyclohexyl Ammonium Salt Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added cyclohexylamine and the resultant mass was strrred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.6 g) with HPLC purity: 98.78%, and diastereomeric impurity 0.51%. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 1.
  • Example 2 Preparation of Rosuvastatin Diisopropyl Ammonium Salt
  • Rosuvastatin acid 2.0 g was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C.
  • diisopropylamine To the solution was added diisopropylamine and the resultant mass was stirred for 30 minutes at about 0°C.
  • the precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.8 g) with HPLC purity: 98.6%, and diastereomeric impurity 0.52%>.
  • the compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%.
  • XRD is as per Figure 2.
  • Example 3 Preparation of Rosuvastatin Isopropyl Ammonium Salt
  • Rosuvastatin acid 2.0 g was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C.
  • isopropylamine To the solution was added isopropylamine and the resultant mass was stirred for 30 minutes at about 0°C.
  • the precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.6 g), with HPLC purity: 98.4%, and diastereomeric impurity 0.5%.
  • the compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%.
  • XRD is as per Figure 3.
  • Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added (s)-(+)- D-methylbenzyl amine and the resultant mass was stirred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.7 g), with HPLC purity: 98.2%, and diastereomeric impurity 0.54%. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 5.
  • Step a) Preparation of rosuvastatin lactone from rosuvastatin diisopropyl ammonium salt.
  • Rosuvastatin diisopropyl ammonium salt (2 gm) was added into mixture of ethyl acetate (10 ml) and water (20 ml) at 25-30°C and the pH of the reaction mass was adjusted to about 3.0 with 6N hydrochloric acid. The layers were separated and the organic layer is washed with water (5 ml). The organic layer was concentrated under vacuum to get an oily crude product, which was mixed with toluene (5 ml). The reaction mass was refluxed for about 6 hours and the solvent was removed under vacuum at 60°C. The residue obtained was stirred with hexane (10 ml) and the separated solid was filtered. Dried the product under vacuum till constant weight at 40-45°C to get rosuvastatin lactone.
  • Step b) Conversion of rosuvastatin lactone to amorphous rosuvastatin calcium.
  • Rosuvastatin lactone as obtained in step a) of Example 6 was dissolved in methanol (10 ml) and water (10 ml). To this solution was added, 8% sodium hydroxide solution until the pH of the reaction mass was about 8.5 to 8.7 and stirred for further 3 hours. After ensuring the absence of rosuvastatin lactone by TLC, solvent was removed under vacuum and the aqueous layer was washed with methyl tert-butyl ether (8 ml).
  • Step c) Conversion of amorphous rosuvastatin calcium to crystalline rosuvastatin calcium
  • Amorphous rosuvastatin calcium (1.0 gm) was added to a mixture of water (5 ml) and acetonitrile (5 ml) at 15°C. The mixture was warmed to 40°C to obtain complete solution. The mixture was then cooled slowly to 25-30°C and stirred for 16 hours. The crystalline product was separated by filtration at ambient temperature and dried at 50°C under vacuum to give rosuvastatin calcium as white crystals, in a yield of 0.68 gm (68%) (XRD as per Figure 7 showed it to be crystalline material).
  • Example 7 Preparation of Crystalline Rosuvastatin Magnesium from Rosuvastatin Diisopropyl Ammonium Salt
  • Rosuvastatin diisopropyl ammonium salt (1.0 g) was added into mixture of ethyl acetate (50 ml) and water (10 ml) and the pH of the reaction mass adjusted to about 3 with hydrochloric acid (6N). The layers were separated and the organic layer is washed with water (3 ml).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des sels des inhibiteurs de HMG CoA réductase, et notamment, des sels d'amine de la rosuvastatine et sur leur utilisation comme intermédiaires dans la préparation du calcium de la rosuvastatine.
EP05702276A 2004-01-19 2005-01-19 Sels des inhibiteurs de hmg-coa reductase et leur utilisation Ceased EP1709008A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN78DE2004 2004-01-19
PCT/IB2005/000114 WO2005077916A1 (fr) 2004-01-19 2005-01-19 Sels des inhibiteurs de hmg-coa reductase et leur utilisation

Publications (1)

Publication Number Publication Date
EP1709008A1 true EP1709008A1 (fr) 2006-10-11

Family

ID=34856862

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05702276A Ceased EP1709008A1 (fr) 2004-01-19 2005-01-19 Sels des inhibiteurs de hmg-coa reductase et leur utilisation

Country Status (2)

Country Link
EP (1) EP1709008A1 (fr)
WO (1) WO2005077916A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
JP2008528542A (ja) * 2005-01-31 2008-07-31 チバ ホールディング インコーポレーテッド ロスバスタチンカルシウム塩の結晶形
TWI345562B (en) 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US9150518B2 (en) 2005-06-24 2015-10-06 Lek Pharmaceuticals, D.D. Process for preparing amorphous rosuvastatin calcium of impurities
CA2630704C (fr) * 2005-12-20 2014-08-19 Lek Pharmaceuticals D.D. Composition pharmaceutique
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
WO2008015563A2 (fr) * 2006-08-04 2008-02-07 Glenmark Pharmaceuticals Limited Sels de rosuvastatine et procédés permettant de les préparer
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
ES2567171T3 (es) 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
CN101570510B (zh) * 2008-04-30 2011-08-31 上海医药工业研究院 喹啉类化合物及其药物组合物、制备方法和应用
WO2010035284A2 (fr) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd Procédé amélioré de préparation de calcium de rosuvastatine
SI2387566T1 (sl) * 2009-01-14 2014-07-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo rosuvastatina
CA2749727A1 (fr) 2009-01-15 2010-07-22 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Procedes de synthese de sels de rosuvastatine
WO2010089770A2 (fr) 2009-01-19 2010-08-12 Msn Laboratories Limited Procédé amélioré d'élaboration d'acide (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophényl)quinolin-3-yl]-3,5-dihydroxy-6(e)-heptènoïque de haute pureté, y compris ses sels pharmaceutiquement acceptables
EP2526099B1 (fr) 2010-01-18 2016-03-30 MSN Laboratories Limited Procédé amélioré pour la préparation d'intermédiaires amides et leur utilisation
US8536330B2 (en) 2010-04-23 2013-09-17 Ranbaxy Laboratories Limited Intermediates for the preparation of HMG-CoA reductase inhibitors
WO2012063115A2 (fr) 2010-11-11 2012-05-18 Jubilant Life Sciences Ltd. Procédé de préparation de rosuvastatine calcique via un nouvel intermédiaire amine
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
WO2012073256A1 (fr) 2010-11-29 2012-06-07 Cadila Healthcare Limited Sels de rosuvastatine
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
WO2012176218A1 (fr) * 2011-06-24 2012-12-27 Ind-Swift Laboratories Limited Procédé de préparation de calcium de rosuvastatine par utilisation d'un nouveau sel d'amine
MX2015013696A (es) * 2013-03-29 2016-02-26 Dsm Sinochem Pharm Nl Bv Sales de amina de pitavastatina y rosuvastatina.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051921A1 (fr) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Sels d'ammonium cristallins de la rosuvastatine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
IL128862A (en) * 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051921A1 (fr) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Sels d'ammonium cristallins de la rosuvastatine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005077916A1 *

Also Published As

Publication number Publication date
WO2005077916A1 (fr) 2005-08-25

Similar Documents

Publication Publication Date Title
US20090036680A1 (en) Salts of hmg-coa reductase inhibitors and use thereof
EP1709008A1 (fr) Sels des inhibiteurs de hmg-coa reductase et leur utilisation
JP5757860B2 (ja) 結晶形態のテノホビルジソプロキシル及びその製造方法
JP2008044948A (ja) ロスバスタチン（ｅ）−７−’４−（４−フルオロフェニル）−６−イソプロピル−２−’メチル（メチルスルホニル）アミノ！ピリミジン−５−イル！（３ｒ，５ｓ）−３，５−ジヒドロキシヘプタ−６−エン酸のカルシウム塩、および、それらの結晶質の中間体の製造方法
US20070191318A1 (en) Process for the preparation of amorphous rosuvastatin calcium
BRPI0410922B1 (pt) processo para a formação de um composto
WO2006035277A2 (fr) Nouvelles methodes de preparation de calcium de rosuvastatine amorphe et nouvelle forme polymorphe de sodium de rosuvastatine
US9233963B2 (en) Method for preparing meropenem using zinc powder
CA2711043A1 (fr) Procede de synthese du bosentan, de ses formes polymorphiques et de ses sels
AU2007208965B2 (en) A process for manufacturing Rosuvastatin Potassium and crystalline and amorphous forms thereof
EP1879862B1 (fr) Sels de magnesium d'inhibiteurs de hmg-coa reductase
WO2008038132A1 (fr) Forme cristalline de sels de diamine de rosuvastatine
WO2017191539A1 (fr) Méthode de préparation de co-cristal de dl-proline de dapagliflozine
WO2005077917A1 (fr) Sels de magnesium amorphes de la rosuvastatine
WO2012176218A1 (fr) Procédé de préparation de calcium de rosuvastatine par utilisation d'un nouveau sel d'amine
JP2013543884A (ja) 高純度の医薬品中間体の製法
US20100069635A1 (en) Rosuvastatin dehydroabietylamine salt
RU2434869C2 (ru) Способ получения абакавира
CA2615691C (fr) Procede de preparation de perindopril cristallin
HU229260B1 (en) Process for preparation of rosuvastatin salts
KR101304640B1 (ko) 신규의 로수바스타틴 엔-메틸벤질아민 염 및 그의 제조방법
EP2419407B1 (fr) Procédé amélioré de préparation de fluvastatine et de sels de celle-ci
JP5334852B2 (ja) アバカビルの製造方法
CN105073713A (zh) 药学上可接受的匹伐他汀胺盐
EP2978744A1 (fr) Sels d'amine de pitavastatine et de rosuvastatine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060821

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070821

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20101218